Broadleaf Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.04M | Hold |
4,787
| – | – | 0.24% | 48 |
|
|
2025
Q4 | $1.09M | Hold |
4,787
| – | – | 0.23% | 48 |
|
|
2025
Q3 | $1.11M | Sell |
4,787
-31
| -0.6% | -$6.31K | 0.23% | 47 |
|
|
2025
Q2 | $894K | Sell |
4,818
-945
| -16% | -$176K | 0.2% | 50 |
|
|
2025
Q1 | $1.21M | Sell |
5,763
-1,800
| -24% | -$350K | 0.32% | 47 |
|
|
2024
Q4 | $1.34M | Sell |
7,563
-335
| -4% | -$61.6K | 0.31% | 43 |
|
|
2024
Q3 | $1.56M | Hold |
7,898
| – | – | 0.37% | 43 |
|
|
2024
Q2 | $1.35M | Sell |
7,898
-10
| -0.1% | -$1.66K | 0.33% | 40 |
|
|
2024
Q1 | $1.44M | Buy |
7,908
+10
| +0.1% | +$1.72K | 0.37% | 44 |
|
|
2023
Q4 | $1.22M | Hold |
7,898
| – | – | 0.36% | 45 |
|
|
2023
Q3 | $1.18M | Sell |
7,898
-33
| -0.4% | -$4.84K | 0.39% | 39 |
|
|
2023
Q2 | $1.07M | Buy |
7,931
+2,500
| +46% | +$367K | 0.35% | 42 |
|
|
2023
Q1 | $866K | Hold |
5,431
| – | – | 0.31% | 43 |
|
|
2022
Q4 | $878K | Hold |
5,431
| – | – | 0.35% | 42 |
|
|
2022
Q3 | $729K | Hold |
5,431
| – | – | 0.3% | 42 |
|
|
2022
Q2 | $832K | Hold |
5,431
| – | – | 0.35% | 40 |
|
|
2022
Q1 | $880K | Hold |
5,431
| – | – | 0.29% | 42 |
|
|
2021
Q4 | $735K | Hold |
5,431
| – | – | 0.23% | 45 |
|
|
2021
Q3 | $586K | Hold |
5,431
| – | – | 0.19% | 48 |
|
|
2021
Q2 | $612K | Hold |
5,431
| – | – | 0.21% | 49 |
|
|
2021
Q1 | $588K | Hold |
5,431
| – | – | 0.22% | 49 |
|
|
2020
Q4 | $582K | Buy |
5,431
+150
| +3% | +$14.4K | 0.23% | 45 |
|
|
2020
Q3 | $463K | Hold |
5,281
| – | – | 0.2% | 48 |
|
|
2020
Q2 | $518K | Hold |
5,281
| – | – | 0.25% | 44 |
|
|
2020
Q1 | $402K | Hold |
5,281
| – | – | 0.26% | 44 |
|
|
2019
Q4 | $468K | Hold |
5,281
| – | – | 0.26% | 43 |
|
|
2019
Q3 | $400K | Sell |
5,281
-1,050
| -17% | -$72K | 0.25% | 45 |
|
|
2019
Q2 | $460K | Hold |
6,331
| – | – | 0.29% | 41 |
|
|
2019
Q1 | $510K | Hold |
6,331
| – | – | 0.36% | 40 |
|
|
2018
Q4 | $584K | Sell |
6,331
-45,103
| -88% | -$3.97M | 0.47% | 40 |
|
|
2018
Q3 | $4.87M | Sell |
51,434
-629
| -1% | -$59.6K | 3.26% | 8 |
|
|
2018
Q2 | $4.82M | Buy |
52,063
+12,039
| +30% | +$1.18M | 3.53% | 7 |
|
|
2018
Q1 | $3.79M | Buy |
40,024
+5,107
| +15% | +$561K | 2.91% | 13 |
|
|
2017
Q4 | $3.38M | Buy |
+34,917
| New | +$3.29M | 2.8% | 11 |
|
Other funds holding ABBV
VCM
VPM
Broadleaf Partners's ABBV Position: Q1 2026 in Review
Broadleaf Partners held its AbbVie (ABBV) position steady in Q1 2026 at 4,787 shares worth $1.04M. The position accounts for 0.24% of the portfolio, ranked #48.
Broadleaf Partners first reported a position in ABBV in Q4 2017 and has held it in 34 quarters since. The position peaked at $4.87M in Q3 2018. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Broadleaf Partners held 4,787 shares of AbbVie worth $1.04M as of Q1 2026.
- Broadleaf Partners left its AbbVie share count unchanged in Q1 2026.
- AbbVie made up 0.24% of Broadleaf Partners's portfolio in Q1 2026, its #48 holding.
- Broadleaf Partners first reported a position in AbbVie in Q4 2017 and has held it in 34 quarters since.
- Broadleaf Partners's AbbVie position peaked at $4.87M in Q3 2018.
- 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Broadleaf Partners's 13F filing for Q1 2026, filed 14 May 2026.